QBiotics

QBiotics is an Australian-based life sciences company dedicated to the research, development, and commercialization of novel drugs for both human and veterinary markets. QBiotics' R&D pipeline is based on compounds derived from Australia’s tropical rainforests. The company’s product focus addresses unmet medical needs in humans and companion animals. QBiotics is currently concentrating on global health priorities in oncology, particularly solid tumors and chronic wound management. Its lead oncology product, tigilanol tiglate, is a novel small molecule administered intratumorally with the potential to treat various solid tumors either as a monotherapy or in combination with checkpoint inhibitor drugs.